Cohen and colleagues also contend that "the SIGN guidelines erroneously state that aspirin also reduces cardiovascular events in acute myocardial infarction and ischaemic stroke".³ The SIGN guidelines are not erroneous: this statement is correct.⁴

I was Chair of the SIGN guideline development group for the SIGN guideline on prophylaxis of venous thromboembolism, and was Chair of SIGN Council, 2002–07.

Gordon Lowe g.d.lowe@clinmed.gla.ac.uk

Division of Cardiovascular and Medical Sciences, University of Glasgow, Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, UK

- Scottish Intercollegiate Guidelines Network. Prophylaxis of venous thromboembolism. Edinburgh: SIGN, 2002. http://www.sign.ac.uk/guidelines/fulltext/62/index.html (accessed May 12, 2008).
- Mackenzie DG, Elders A, Wild S, Muir R. Thromboprophylaxis for patients at high risk of VTE. Lancet 2008; 371: 1911.

- Cohen AT, Tapson VF, Anderson FA, on behalf of the ENDORSE Steering Committee and Investigators. Thromboprophylaxis for patients at high risk of VTE. Lancet 2008; 371: 1911–13.
- 4 Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BM*J 2002; **324**: 71–86.

Studying medicine with a criminal record

The question as to whether a student with a criminal conviction can study medicine (July 12, p 36)¹ can be answered with a resounding yes. Canada's most famous physician, Sir William Osler, was acceptable to McGill despite a criminal conviction. After a cruel and potentially dangerous prank on the school matron, he and

other boys had been charged with assault, probably spent a few nights in jail, and were fined with costs.² Thus a student applicant with a criminal record should be assessed with care, but not necessarily banned from admission.

I declare that I have no conflict of interest.

Peter Warren

5 River Lane, Winnipeg, MB R2M 3Y8, Canada

- The Lancet. Can a student with a criminal conviction study medicine? Lancet 2008; 372: 88.
- Bliss M. William Osler: a life in medicine. Toronto: University of Toronto Press, 1999: 36–37.

Department of Error

Mouton R, Finch D, Davies I, Binks A, Zacharowski K. Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study. Lancet 2008; 371: 475–82—In this Article (Feb 9), there were some errors in table 1. The correct version appears below.

	Off-pump study group					On-pump study group				
	Control (n=1532)	Aprotinin (n=125)	Р	Tranexamic acid (n=2015)	Р	Control (n=485)	Aprotinin (n=1209)	Р	Tranexamic acid (n=3740)	Р
Men	1249 (82%)	86 (69%)	0.001	1643 (82%)	0.993	360 (74%)	752 (62%)	<0.0001	2754 (74%)	0.78
Angina CCS3 or 4	788 (52%)	76 (61%)	0.046	902 (45%)	<0.0001	181 (37%)	254 (21%)	<0.0001	1336 (36%)	0.49
Dyspnoea MYHA iii or iv	465 (30%)	60 (48%)	<0.0001	577 (29%)	0.269	162 (34%)	573 (47%)	<0.0001	1393 (37%)	0.10
Diabetes mellitus	272 (18%)	33 (26%)	0.017	402 (20%)	0.097	72 (15%)	132 (11%)	0.025	593 (16%)	0.56
Hypertension	976 (64%)	83 (68%)	0.412	1432 (72%)	<0.0001	286 (59%)	597 (50%)	0.001	2214 (59%)	0.95
Pulmonary disease	157 (10%)	20 (16%)	0.047	227 (11%)	0.332	46 (10%)	152 (13%)	0.079	432 (12%)	0.18
Neurological disease	99 (7%)	10 (8%)	0.507	145 (7%)	0.391	30 (6%)	122 (10%)	0.012	327 (9%)	0.06
Carotid bruits	49 (3%)	5 (4%)	0.632	69 (3%)	0.693	11 (2%)	26 (2%)	0.876	85 (2%)	0.99
Preoperative arrhythmia	86 (6%)	10 (8%)	0.275	77 (4%)	0.012	50 (10%)	221 (18%)	<0.0001	415 (11%)	0.61
Unstable angina	93 (6%)	31 (25%)	<0.0001	155 (8%)	0.061	31 (6%)	133 (11%)	0.004	249 (7%)	0.82
Poor LVEF	62 (4%)	13 (11%)	0.001	67 (3%)	0.242	15 (3%)	85 (8%)	0.001	189 (5%)	0.07
Emergency admission	17 (1%)	16 (13%)	<0.0001	18 (1%)	0.519	17 (4%)	149 (12%)	<0.0001	60 (2%)	0.00
Isolated CABG	1474 (96%)	114 (91%)	0.009	1984 (99%)	<0.0001	281 (58%)	159 (13%)	<0.0001	2120 (57%)	0.60
Redo procedure	28 (2%)	27 (22%)	<0.0001	30 (2%)	0.431	20 (4%)	327 (27%)	<0.0001	45 (1%)	<0.00
Reoperation	69 (5%)	4 (3%)	0.498	43 (2%)	<0.0001	30 (6%)	76 (7%)	0.887	161 (4%)	0.06
Postoperative renal dysfunction	75 (5%)	20 (16%)	<0.0001	115 (6%)	0.287	23 (5%)	139 (12%)	<0.0001	226 (6%)	0.25
In-hospital death	18 (1%)	6 (5%)	0.003	18 (1%)	0.409	5 (1%)	80 (7%)	<0.0001	69 (2%)	0.20
ACE inhibitors given	815 (53%)	86 (69%)	0.001	1293 (64%)	<0.0001	190 (39%)	488 (40%)	0.652	1749 (47%)	0.00
Age at surgery (years)	64.1 (9.6)	65-9 (11-8)	0.048	65.3 (9.1)	<0.0001	63.8 (12.0)	62-8 (16-0)	0.220	65-4 (10-6)	0.00
Weight (kg)	82-8 (14-1)	80-6 (16-2)	0.103	82.9 (14.7)	0.844	80-0 (14-5)	75-9 (16-6)	<0.0001	80-4 (15-2)	0.61
Preoperative creatinine (µmol/L)	109-5 (19-8)	105-8 (23-8)	0.047	106.1 (20.4)	<0.0001	108-7 (20-5)	108-1 (25-2)	0.660	107.5 (20.9)	0.25
Postoperative creatinine (µmol/L)	121-0 (46-2)	142-1 (70-8)	<0.0001	122-0 (54-9)	0.584	123-2 (50-7)	139-1 (74-8)	<0.0001	123.4 (52.9)	0.94
EuroSCORE	3.9 (2.6)	6.8 (3.4)	<0.0001	3.8 (2.7)	0.338	4.9 (3.0)	7.9 (3.3)	<0.0001	4.9 (2.9)	0.87